VIX Short-Term Futures ETN Ipath (VXX) 25.63

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
VIX Short-Term Futures ETN Ipath (VXX) 25.63 $VXX

Welcome Back, Volatility
Russ Koesterich, CFA - Seeking Alpha - Tue Mar 31, 3:25PM CDT
Our experts explain why volatility is making a comeback and how to get your portfolio ready for more ups and downs. As my team and I conduct our 2015 macroeconomic outlook meetings, we have made a conscientious effort to drive this message home:...
SPY: 206.43 (-1.82), VXX: 25.63 (+0.67)

The VIX In 1 Month?
Dave Allen - Seeking Alpha - Tue Mar 31, 7:54AM CDT
"Markets Love Volatility" - Christine Lagarde The VIX was up 16% last week, as the S&P 500 dropped for 4 straight days before recovering with a modest gain on Friday with a little help from Janet Yellen. It was the worst week for the...
VXX: 25.63 (+0.67)

Shorting The VIX: How To Protect Profits In A Volatility Spike
Force Majeure - at Seeking Alpha - Mon Mar 30, 4:00PM CDT

VXX: 25.63 (+0.67), RUSS: 12.11 (+0.43), VXZ: 12.57 (+0.11), SPXL: 88.44 (-2.36), PSQ: 57.55 (+0.59)

After Yesterday's Decline of 3.03%, iPATH S&P 500 VIX Short-Term Futures ETN Offers Investors Better Value
Comtex SmarTrend(R) - Mon Mar 30, 3:52PM CDT
iPATH S&P 500 VIX Short-Term Futures ETN (NYSE:VXX) traded in a range yesterday that spanned from a low of $24.82 to a high of $25.19. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $24.88 on volume of 28.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VXX: 25.63 (+0.67)

Watch for iPATH S&P 500 VIX Short-Term Futures ETN to Potentially Rebound After Falling 3.03% Yesterday
Comtex SmarTrend(R) - Mon Mar 30, 3:51PM CDT
iPATH S&P 500 VIX Short-Term Futures ETN (NYSE:VXX) traded in a range yesterday that spanned from a low of $24.82 to a high of $25.19. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $24.88 on volume of 28.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VXX: 25.63 (+0.67)

Stocks See Relief Rally As Geopolitically Risky Weekend Passes - What's Next?
Markos Kaminis - at Seeking Alpha - Mon Mar 30, 12:32PM CDT

VTI: 107.25 (-0.98), USO: 16.84 (-0.39), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), VXX: 25.63 (+0.67), GLD: 113.66 (-0.09), OIL: 10.05 (-0.22), DIA: 177.58 (-1.81), PHYS: 9.78 (-0.01), IWM: 124.37 (-0.40), UUP: 25.90 (+0.04)

Market Outlook - Where We Stand Now
Price Headley, CFA - at Seeking Alpha - Mon Mar 30, 7:23AM CDT
Even with Friday's bounce, the bulls couldn't do anywhere near enough to undo Wednesday's damage. All told, the S&P 500 (SPX) (NYSEARCA: SPY ) lost 2.2% last week. The results look grim, and several of our key technical indicators are at or near...
SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), VXX: 25.63 (+0.67), DIA: 177.58 (-1.81), IWM: 124.37 (-0.40), UUP: 25.90 (+0.04)

Complacency Reigns Supreme - Nothing Can Possibly Go Wrong, Right?
Charles Hugh Smith - at Seeking Alpha - Sun Mar 29, 7:35AM CDT
One of the more remarkable features of the Bull market in stocks is the ascendancy of complacency and the banishing of fear. Take a look at this chart of the "fear index," the VIX - more properly, a measure of volatility: The VIX...
TVIZ: 19.48 (+0.34), TVIX: 1.70 (+0.08), XVZ: 28.83 (+0.01), VIXM: 61.09 (+0.58), XVIX: 17.02 (+0.07), ZIV: 42.08 (-0.41), VXX: 25.63 (+0.67), IVOP: 38.01 (unch), UVXY: 15.05 (+0.74), VIIX: 34.54 (+0.84), CVOL: 0.84 (+0.06), VXZ: 12.57 (+0.11), VIIZ: 17.43 (+0.30), XXV: 38.28 (unch), VIXY: 17.01 (+0.43), SVXY: 68.04 (-1.70), XIV: 34.64 (-0.89)

Volatility: Up She Rises
Eric Parnell, CFA - at Seeking Alpha - Sat Mar 28, 1:34AM CDT

SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), VXX: 25.63 (+0.67), DIA: 177.58 (-1.81)

The Fed Is Trapped
Harry Long - at Seeking Alpha - Fri Mar 27, 6:39AM CDT

VXX: 25.63 (+0.67), TLT: 130.69 (+0.28)

Friday Freefall Possible As Slew Of Middle East Issues Weigh On Weekend
Markos Kaminis - at Seeking Alpha - Fri Mar 27, 3:00AM CDT

VTI: 107.25 (-0.98), USO: 16.84 (-0.39), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), VXX: 25.63 (+0.67), GLD: 113.66 (-0.09), DIA: 177.58 (-1.81), IWM: 124.37 (-0.40), UUP: 25.90 (+0.04)

Downtrend Call Working As iPATH S&P 500 VIX Short-Term Futures ETN Stock Falls 12.0% (VXX)
Comtex SmarTrend(R) - Thu Mar 26, 10:11AM CDT
SmarTrend identified a Downtrend for iPATH S&P 500 VIX Short-Term Futures ETN (NYSE:VXX) on February 19th, 2015 at $30.61. In approximately 1 month, iPATH S&P 500 VIX Short-Term Futures ETN has returned 11.98% as of today's recent price of $26.94.
VXX: 25.63 (+0.67)

SmarTrend Watching for Potential Pullback in Shares of iPATH S&P 500 VIX Short-Term Futures ETN After 4.45% Gain
Comtex SmarTrend(R) - Wed Mar 25, 3:53PM CDT
iPATH S&P 500 VIX Short-Term Futures ETN (NYSE:VXX) traded in a range yesterday that spanned from a low of $24.88 to a high of $26.30. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $25.99 on volume of 53.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VXX: 25.63 (+0.67)

iPATH S&P 500 VIX Short-Term Futures ETN Rises 4.45% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Mar 25, 3:52PM CDT
iPATH S&P 500 VIX Short-Term Futures ETN (NYSE:VXX) traded in a range yesterday that spanned from a low of $24.88 to a high of $26.30. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $25.99 on volume of 53.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VXX: 25.63 (+0.67)

Connecting The Dots: The Stock Market Hot Potato: Volatility, The VIX And You
John Mauldin - Seeking Alpha - Tue Mar 24, 12:59PM CDT
“When did Noah build the Ark, Gladys? Before the rain, before the rain.” —Nathan Muir (Robert Redford), in Spygame If you’ve ever walked a dog, you know about the zigzag path that dogs take down a sidewalk. After all,...
VXX: 25.63 (+0.67)

Time To Ratchet Up Risk Management
Clark Capital Management Group - at Seeking Alpha - Mon Mar 23, 9:07PM CDT
Volatility Is Back in Vogue March 9th marked the sixth anniversary of the current bull market. Since the average bull market lasts only 3.8 years, we think it may be time to take a look at client portfolios and decide whether it makes sense to...
VXX: 25.63 (+0.67)

Fed's Fischer Says 2015 Rate Hike Wouldn't Be Followed by Regular Increases
at The Street - Mon Mar 23, 2:01PM CDT
CNBC 'Fast Money Halftime' traders dissect what a rate hike would mean for U.S. stocks and learn what a contrarian fund manager is buying.
F: 16.14 (-0.02), VXX: 25.63 (+0.67), TM: 139.89 (-2.66), UUP: 25.90 (+0.04), TLT: 130.69 (+0.28), TBT: 41.87 (-0.20), UAL: 67.25 (-0.94), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), JOE: 18.56 (+0.38), DIA: 177.58 (-1.81), ETFC: 28.55 (+0.31), FXE: 105.71 (-0.61), IWM: 124.37 (-0.40), XLF: 24.11 (-0.17), TWTR: 50.08 (+0.19), AMTD: 37.26 (+0.04), SCHW: 30.44 (+0.08)

Market Outlook - The Fed Gives A Boost
Price Headley, CFA - Seeking Alpha - Mon Mar 23, 7:52AM CDT
Thanks to a little help from the Federal Reserve on Wednesday, the market broke out of a three-week-old bearish rut, and in the process may have rekindled a bigger uptrend. In fact, technically speaking, the uptrend is back underway. We'll handicap...
SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), VXX: 25.63 (+0.67), DIA: 177.58 (-1.81), IWM: 124.37 (-0.40)

Weekly ETF Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 3:12PM CDT

VNM: 16.88 (-0.02), USO: 16.84 (-0.39), GDXJ: 22.70 (-0.12), VXX: 25.63 (+0.67), OIL: 10.05 (-0.22), SIVR: 16.36 (-0.08), SLV: 15.93 (-0.05), GDX: 18.24 (-0.23), EWZ: 31.37 (+0.28), UUP: 25.90 (+0.04)

Investors Should Stick With Health Care Stocks, eBay Has Downside
at The Street - Thu Mar 19, 1:56PM CDT
The CNBC ‘Fast Money Halftime’ trading panel agrees that health care stocks still have an upside, while an analyst explains his decision to downgrade eBay.
KMI: 42.06 (-0.01), BIIB: 422.24 (-9.38), MNST: 138.40 (-2.04), EWG: 29.84 (-0.52), VXX: 25.63 (+0.67), NKE: 100.33 (-0.56), UNH: 118.29 (-2.71), KORS: 65.75 (-0.51), TLT: 130.69 (+0.28), GOOG: 548.00 (-4.03), COH: 41.43 (-0.16), SPY: 206.43 (-1.82), EBAY: 57.68 (-0.24), DIA: 177.58 (-1.81), GOOGL: 554.70 (-6.44), FL: 63.00 (-0.61), FXE: 105.71 (-0.61), AAPL: 124.43 (-1.94), FB: 82.21 (-0.98), TIF: 88.01 (-0.58), XLU: 44.43 (+0.01), UUP: 25.90 (+0.04), XRT: 101.04 (-0.54), ARO: 3.47 (+0.14), XLV: 72.50 (-1.28), CELG: 115.28 (-4.74), GES: 18.59 (-0.30), UA: 80.75 (+0.84), QQQ: 105.60 (-1.13), BONT: 6.96 (-0.02), GILD: 98.13 (-2.56), CRI: 92.47 (+0.63), IWM: 124.37 (-0.40)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading